DM1001
/ Fosun Pharma, Fosun Wanbang Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 24, 2026
Shanghai Fosun Pharmaceutical said its subsidiary Fosun Wanbang has received approval from China’s National Medical Products Administration to begin clinical trials of DM1001, a chemical drug candidate for treating the signs and symptoms of Parkinson’s disease.
(TipRanks)
- "The company plans to launch a Phase I trial in mainland China once preparatory conditions are met, marking a new step in its central nervous system pipeline."
New P1 trial • Parkinson's Disease
1 to 1
Of
1
Go to page
1